Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Christine Rode Andreasen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Andreas Andersen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Filip Krag Knop in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
tested in the other CVOTs ( Table 1 ), the short follow-up period of 2 years and the highest percentage of participants on statin therapy ( Table 2 ). The EXSCEL trial did not find any significant difference in the primary outcome between treatment with
Department of Nuclear Medicine, CHU de Bordeaux, Pessac, France
INRA, Nutrition et Neurobiologie Intégrée, UMR1286, Bordeaux, France
Search for other papers by J Brossaud in
Google Scholar
PubMed
INRA, Nutrition et Neurobiologie Intégrée, UMR1286, Bordeaux, France
Search for other papers by V Pallet in
Google Scholar
PubMed
Department of Nuclear Medicine, CHU de Bordeaux, Pessac, France
INRA, Nutrition et Neurobiologie Intégrée, UMR1286, Bordeaux, France
Search for other papers by J-B Corcuff in
Google Scholar
PubMed
adipocytes . Journal of Nutrition 2008 138 1004 – 1009 . 10.1093/jn/138.6.1004 95 Iacobazzi V Convertini P Infantino V Scarcia P Todisco S Palmieri F. Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine
Department of Research and Development, Växjö, Sweden
Primary Care, Växjö, Sweden
Search for other papers by Eva O Melin in
Google Scholar
PubMed
Search for other papers by Jonatan Dereke in
Google Scholar
PubMed
Department of Research and Development, Växjö, Sweden
Department of Internal Medicine, Endocrinology and Diabetes, Central Hospital, Växjö, Sweden
Search for other papers by Maria Thunander in
Google Scholar
PubMed
Search for other papers by Magnus Hillman in
Google Scholar
PubMed
and insulin resistance. Lipid-lowering drugs (LLD) were hydroxy-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) (C10AA). Indications for LLD were TC >4.5 mmol/L (>1.74 mg/dL) and/or LDL >2.5 mmol/L (>97 mg/dL) according to local
Faculty of Medicine, University of Oslo, Oslo, Norway
Search for other papers by Espen Nordheim in
Google Scholar
PubMed
Faculty of Medicine, University of Oslo, Oslo, Norway
Metabolic and Renal Research Group, Faculty of Health Sciences, UiT- The Arctic University of Norway, Tromsø
Search for other papers by Trond Geir Jenssen in
Google Scholar
PubMed
diabetes A comprehensive care is recommended for the management of diabetes patients in the recent KDIGO clinical practice guidelines ( 21 ), including statins to all patients with diabetes and kidney disease regardless of cholesterol levels to prevent
Search for other papers by Jan Kvasnička in
Google Scholar
PubMed
Search for other papers by Ondřej Petrák in
Google Scholar
PubMed
Search for other papers by Tomáš Zelinka in
Google Scholar
PubMed
Search for other papers by Judita Klímová in
Google Scholar
PubMed
Search for other papers by Barbora Kološová in
Google Scholar
PubMed
Search for other papers by Květoslav Novák in
Google Scholar
PubMed
Search for other papers by David Michalský in
Google Scholar
PubMed
Search for other papers by Jiří Widimský Jr in
Google Scholar
PubMed
Search for other papers by Robert Holaj in
Google Scholar
PubMed
Angiotensin receptor blockers ( n (%)) 4 (17) 1 (4) NS α-blockers ( n (%)) 8 (33) 0 (0) <0.005 Central agonists ( n (%)) 2 (8) 0 (0) NS Aldosterone antagonists ( n (%)) 1 (4) 0 (0) NS Statins ( n (%)) 8
Search for other papers by Christian Trummer in
Google Scholar
PubMed
Search for other papers by Stefan Pilz in
Google Scholar
PubMed
Search for other papers by Verena Schwetz in
Google Scholar
PubMed
Search for other papers by Barbara Obermayer-Pietsch in
Google Scholar
PubMed
Search for other papers by Elisabeth Lerchbaum in
Google Scholar
PubMed
cardiovascular risk 62 ± 11 years OR 2.47 (1.55–3.93) for men with 25(OH)D <25 nmol/L compared to >75 nmol/L ↑TT, ↑FAI ↓SHBG Age, BMI, wine consumption, smoking, beta-blocker use, statin use and diabetes Heijboer et al . ( 86 ) 183 men (101 men
Search for other papers by Qian Deng in
Google Scholar
PubMed
Search for other papers by Yue Zhu in
Google Scholar
PubMed
Search for other papers by Mengmeng Zhang in
Google Scholar
PubMed
Search for other papers by Aihua Fei in
Google Scholar
PubMed
Search for other papers by Jiaqi Liang in
Google Scholar
PubMed
Search for other papers by Jinjin Zheng in
Google Scholar
PubMed
Search for other papers by Qingping Zhang in
Google Scholar
PubMed
Search for other papers by Tong Cheng in
Google Scholar
PubMed
Search for other papers by Xia Ge in
Google Scholar
PubMed
statins and fibrates in the management of cardiovascular risk . Current Opinion in Lipidology 2009 20 505– 511 . ( https://doi.org/10.1097/MOL.0b013e328332e9ef ) 105 Xu N Wang Q Jiang S Wang Q Hu W Zhou S Zhao L Xie L Chen J Wellstein
Search for other papers by E T Aristizabal Prada in
Google Scholar
PubMed
Search for other papers by C J Auernhammer in
Google Scholar
PubMed
well as several other drugs like phenformin, resveratrol, berberine, statins, epigallocatechin gallate and capsaicin, have been suggested to exert anti-tumoural effects by activation of AMPK and inhibition of mTOR ( 93 ). In the human NET cell lines